306 related articles for article (PubMed ID: 12622602)
1. Risk for myopathy with statin therapy in high-risk patients.
Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
[TBL] [Abstract][Full Text] [Related]
2. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Jamal SM; Eisenberg MJ; Christopoulos S
Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
5. Statin induced myopathy. Use of statins with ciclosporin.
Camilleri B
BMJ; 2008 Dec; 337():a2788. PubMed ID: 19050019
[No Abstract] [Full Text] [Related]
6. Statin-associated myopathy.
Hamilton-Craig I
Med J Aust; 2001 Nov; 175(9):486-9. PubMed ID: 11758079
[TBL] [Abstract][Full Text] [Related]
7. Safety considerations for statins.
Bolego C; Baetta R; Bellosta S; Corsini A; Paoletti R
Curr Opin Lipidol; 2002 Dec; 13(6):637-44. PubMed ID: 12441888
[TBL] [Abstract][Full Text] [Related]
8. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.
Jacobson TA
Expert Opin Drug Saf; 2003 May; 2(3):269-86. PubMed ID: 12904106
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
10. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.
Mohassel P; Mammen AL
Muscle Nerve; 2013 Oct; 48(4):477-83. PubMed ID: 23519993
[TBL] [Abstract][Full Text] [Related]
11. Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy.
Mo L; He J; Yue Q; Dong B; Huang X
J Clin Pharm Ther; 2015 Apr; 40(2):245-8. PubMed ID: 25512016
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
13. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization.
Shanahan RL; Kerzee JA; Sandhoff BG; Carroll NM; Merenich JA
Pharmacotherapy; 2005 Mar; 25(3):345-51. PubMed ID: 15843281
[TBL] [Abstract][Full Text] [Related]
14. An overview of statin-induced myopathy and perspectives for the future.
Nikolic D; Banach M; Chianetta R; Luzzu LM; Pantea Stoian A; Diaconu CC; Citarrella R; Montalto G; Rizzo M
Expert Opin Drug Saf; 2020 May; 19(5):601-615. PubMed ID: 32233708
[No Abstract] [Full Text] [Related]
15. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
Harper CR; Jacobson TA
Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
17. How well tolerated are lipid-lowering drugs?
Tomlinson B; Chan P; Lan W
Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634
[TBL] [Abstract][Full Text] [Related]
18. Statin-induced myopathy: the two faces of Janus.
Arora R; Liebo M; Maldonado F
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):105-12. PubMed ID: 16891287
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyolysis and HMG-CoA reductase inhibitors.
Omar MA; Wilson JP; Cox TS
Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
[TBL] [Abstract][Full Text] [Related]
20. Statin-drug interactions: not a class effect.
Frishman WH; Horn J
Cardiol Rev; 2008; 16(4):205-12. PubMed ID: 18562811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
